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Figure 1. Improved GHVD-free Survival by Blocking CD28
Abstracts / Biol Blood Marrow Transplant 20 (2014) S45eS56S56Results: Complete bacterial/fungal pyrosequencing and bac-
terial groupqPCRwasperformedon10patients (4 iGVHD, 6no
GVHD). As evidenced by 16S rRNA sequencing, only patients
with iGVHD developed signiﬁcant expansion of ENTERO and a
signiﬁcant decrease in SCFA Clostridia prior to the diagnosis of
iGVHD. Bacterial group qPCR conﬁrmed these ﬁndings: pa-
tients with GVHD had signiﬁcantly higher ENTERO (p< 0.01,
Mann Whitney) and signiﬁcantly lower EREC and CLEPT
(subgroups of the SCFA Clostridia) (P<0.01) than non-GVHD
counterparts. Of the clinical characteristics recorded, clinda-
mycin treatment, which is effective against Clostrida spp, was
the most strongly associated with the development of iGVHD
Conclusion: Expansion of pro-inﬂammatory ENTERO and
decreases in anti-inﬂammatory Clostridia (CLEPT and EREC)
are associatedwith iGVHD in pediatric BMT patients. Medical
therapies such as chemotherapy and/or antibiotics may
disturb the baseline gut microbiota and make certain
patients predisposed to the development of iGVHD. Real-
timemonitoring of the gut microbiota (bacterial group qPCR)
has great potential as a biomarker for iGVHD.
1. Eriguchi et al. Blood. Jul 5 2012;120(1):223-231.
2. Atarashi et al. Nature. Aug 8 2013;500(7461):232-236
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Introduction: We have previously shown, using a non-hu-
man primate (NHP) model, that inhibition of CD28:CD80/86
costimulation with CTLA4-Ig could prevent GVHD, and this
strategy is now being tested in a Phase 2 clinical trial. Despite
the potential efﬁcacy of CTLA4-Ig, there is concern that it may
have off-target effects, given its inhibition of both (+) CD28
signaling and (-) CTLA4 signaling. In order to speciﬁcally target
CD28, we have developed an antagonistic humanized anti-
CD28 monovalent Fab’ antibody (FR104). Here we investigate
the efﬁcacy and mechanism of action of FR104 in NHP, to
potentially facilitate its most rapid clinical translation.
Methods: NHP underwent MHC-mismatched HCT after
myeloablative TBI. They were transplanted with GCSF-mobi-
lized PBSCs (4  1x108 TNC/kg and 2  0.5x 107 CD3+ T
cells/kg). GVHD prophylaxis was with FR104 monotherapyFigure 2. CD28-blockade-mediated Inhibition of GVHD Correlates with Control of CD8
Post-transplant. B. Inhibition of CD8+ proliferation correlates with GVHD-free surviv(5mg/kg/wk IV, resulting in <1% CD28 expression) or with
FR104 +mTOR inhibitionwith rapamycin, andwere compared
to two controls groups (untreated recipients and rapamycin
monotherapy). Clinical and histologic GVHD was monitored
and longitudinal immunologic analysis performed.
Results: Untreated controls (n ¼ 5) developed rapid, severe
AGVHD (MST¼7 d). Rapamycin alone (n ¼ 6) partially
protected recipients, with GI-predominant AGVHD (MST ¼
14 d, Fig. 1). FR104 monotherapy showed statistically
signiﬁcant prolongation in survival (MST ¼ 27 days, n ¼ 3)
compared to rapamycin (p ¼ 0.05) and untreated controls
(p¼0.02), with breakthrough GVHD occurring in two animals
(liver and skin). In contrast, FR104 + rapamycin (n ¼ 3)
controlled GVHD, with all recipients reaching the timed
terminal analysis at day +33-35 without clinical disease
(p ¼ 0.017 vs. untreated, p ¼ 0.013 versus rapamycin alone).
Our previous work has documented a major role for T cell
proliferation (by Ki-67 expression) in GVHD, with untreated
controls demonstrating rampant CD8+ proliferation (89  5%
Ki-67+ CD8+ T cells at terminal analysis (d +6) vs. 4% pre-
transplant, Fig. 2A). Rapamycin and FR104 monotherapy both
partially controlled proliferation (9% 4% and 14% 8%Ki-67+
CD8+ on d +6) with rapamycin + FR104 combination therapy
resulting in further control (3.5% 0.3% Ki-67+ CD8+ on d +6).
Moreover, the degree of CD8+ proliferation correlated closely
with GVHD-free survival (Fig. 2B), suggesting that Ki-67
expression may be a predictive biomarker of this disease.
Implications: These results show that speciﬁc blockade of
CD28 can inhibit NHP GVHD and when combined with
rapamycin, can effectively control this disease for the length of
dual therapy. Importantly, clinical control of GVHDwith FR104
correlatedwithnormalizationof Tcell proliferation.Our results
suggest that selective CD28 blockade may be a safe and effec-
tive adjunctive strategy to inhibit GVHD-associated T cell acti-
vation, and is deserving of clinical evaluation in patients
undergoing HCT.+ T cell Proliferation. A. % of Proliferating CD8þ T cells Measured Longitudinally
al.
